ATGC Inc.

Ypsilanti, MI · Biotech · Private

Recombinant human α-galactosidase A (GalA) enzyme produced in transgenic chicken eggs as a bioreactor for Fabry disease treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Ypsilanti, MI
Total capital: $7M

Federal grants: $7M; 14 awards · 2017–2023; Rank in peer group#502 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 1 pending

Capital timeline

Latest events

May 2023Federal grantHealth and Human S · Phase II · Novel methods to improve nuclease mediated homologous recombination$940K
Mar 2023Federal grantHealth and Human S · Phase I · Structure-based computational engineering of saCas9 PAM requirement$275K
Sep 2022Federal grantHealth and Human S · Phase II · Novel methods to improve nuclease mediated homologous recombination, Administrative suppl$313K
Aug 2022Federal grantHealth and Human S · Phase I · Rapid egg bioreactor construction for Fabry disease therapeutics$260K
Aug 2022Federal grantHealth and Human S · Phase I · Rapid egg bioreactor construction for Fabry disease therapeutics$260K
Apr 2022Federal grantHealth and Human S · Phase II · Novel methods to improve nuclease mediated homologous recombination$855K
Sep 2019Federal grantHealth and Human S · Phase II · A nanoparticle delivery system for CRISPR/Cas9 based therapeutics$733K

Show 7 earlier federal awards

Sep 2018Federal grantHealth and Human S · Phase II · A nanoparticle delivery system for CRISPR/Cas9 based therapeutics$1.5M
Aug 2018Federal grantHealth and Human S · Phase II · A nanoparticle delivery system for CRISPR/Cas9 based therapeutics$750K
Sep 2017Federal grantHealth and Human S · Phase I · Ground state rabbit pluripotent stem cells$226K
Sep 2017Federal grantHealth and Human S · Phase I · Ground state rabbit pluripotent stem cells$226K
Aug 2017Federal grantHealth and Human S · Phase I · Novel methods to improve nuclease mediated homologous recombination$225K
Aug 2017Federal grantHealth and Human S · Phase I · Novel methods to improve nuclease mediated homologous recombination$225K
May 2017Federal grantHealth and Human S · Phase II · A nanoparticle delivery system for CRISPR/Cas9 based therapeutics$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 1

Sep 5, 2019PendingTandem AntibodiesUSPTOApplication 16291958

FORAGR MEDICINES, INCSimilar federal contract value in Biotech · null in contracts
PROMUTECH PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
PROGENRA INCSimilar federal contract value in Biotech · null in contracts
VONA THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
ASTERO ERADO INCSimilar federal contract value in Biotech · null in contracts
CONIFER POINT PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.